Meeting Coverage

Meeting Coverage

Aaron Gerds: What Does the Future Hold for Pacritinib?

Aaron Gerds, MD, MS, shares results from the PAC203 trial, which enrolled patients with high-risk and heavily refractory myelofibrosis.

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients With AML

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...

Naveen Pemmaraju: A New Option for Myelofibrosis?

Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
David Sallman, MD

David Sallman: Early Results of 5F9 in AML and MDS

David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...

Catherine Diefenbach: Polatuzumab Vedotin for Follicular Lymphoma

Dr. Diefenbach shares results from a phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide for relapsed/refractory follicular lymphoma.

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.